OBJECTIVES: To assess the cost-utility of rasagiline or entacapone (COMT) as adjunctive therapies to levodopa (LD) versus carbidopa/levodopa/entacapone (LCE) versus standard LD monotherapy in patients with advanced PD and motor fluctuations in the US. As PD progresses, patients and their families experience substantial health and economic burdens. Because motor fluctuations are linked to poor quality of life and higher health care costs minimizing off-time is an effective strategy for reducing costs associated with PD. METHODS: A two-year Markov model was utilized to examine the cost-effectiveness of advanced PD treatments. Patients may transition therapy every four months. Transition probabilities were obtained from clinical trial data. Medical costs, drug costs and utility weights were from published literature.
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COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
Toumi M 1 , Lamure M 1 , Grishchenko M 2 , Cochran J 2 , Rive B 1 1 University Claude Bernard Lyon I, Villeurbanne Cedex, France, 2 Lundbeck SAS, Paris, France OBJECTIVES: To assess the cost-effectiveness of memantine, compared with standard care, in moderate to severe Alzheimer's disease (AD) patients. METHODS: A costutility analysis was conducted based on a 3-state Markov model, which simulated 5year evolution of pre Full-Time-Care (FTC) patients with and without memantine treatment in addition to any background AD therapy, in terms of time-to-FTC, Quality-Adjusted-Life-Years (QALYs), and cost. Transition from the pre-FTC to the FTC state was modelled using new predictive equations estimating time-to-FTC based on clinical assessment of cognition, function, and behaviour. The equations were derived from cohort of patients with dementia followed for four years. Treatment effect was estimated based on the published meta-analysis of six memantine RCTs. Both health utilities (EQ-5D) and resource utilization for the model came from a Scandinavian Study of Cost and Quality of Life in AD. Costs were valued from the societal perspective, and covered routine patient management, hospitalization, social community services, institutionalisation, medications, loss in productivity, and leisure time. Memantine cost was accounted for until patients required FTC (conservative). Costs and benefits were discounted at an annual rate of 3%. Results were reported in Euros (NOK), 2008. The model underwent extensive stochastic and one-way sensitivity analyses testing the impact of model assumptions and changes in input values for treatment effect, health utilities, cost, and discounting rates. RESULTS: Memantine was associated with a longer time-to-FTC of 21 days, QALYs gains of 0.02 and a cost saving of above a-900 ( 7,500NOK). Lower costs in memantine group were due to prolonged pre-FTC time and offset drug acquisition cost. Memantine was costeffective at a40,000 (300,000NOK) thresholds (72.86%). The sensitivity analyses confirmed the robustness of the base-case scenario. CONCLUSIONS: Memantine is associated with higher benefits for no additional costs relative to standard care, and is a cost-effective treatment.
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COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN
Arbizu T 1 , Piñol C 2 , Casado V 3 1 Hospital de Bellvitge, Hospitalet de Llobergat, Barcelona, Spain, 2 Bayer HealthCare, Barcelona, Spain, 3 Hospital de Bellvitge, Hospitalet del LLobregat, Barcelona, Spain OBJECTIVES: Estimate the cost-utility of interferon beta 1B (IFNB-1b) in patients with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS). METHODS: A Markov model was developed using the epidemiology and treatment of CIS and MS. The model simulates outcomes over time horizons ranging from 2 years to lifetime. A hypothetical cohort of 1,000 patients with incident CIS, with initial health states defined by Kurtzke's Expanded Disability Symptom Scale (EDSS), was specified. The cohort was assumed alternatively to be treated with IFNB-1b (250 mg eod) following an initial demyelinating event suggestive of MS or not treated until confirmation of MS.Data from study BENEFIT was used to model EDSS progression over time and transitions from CIS to MS. Exacerbations (relapses) were estimated from BENEFIT and published natural history data. Following transition to MS, all patients were assumed to be treated with IFNB-1b until EDSS 6.5. Direct and indirect medical costs of MS treatment and IFNB-1b were estimated from published literature and pricing schedules. Patient utilities were derived from EQ-5D data , supplemented by published data defined by EDSS score and relapse occurrence. Mortality was estimated using life tables and EDSS data. Costs (a2008) and outcomes were discounted at 3% per annum. Sensitivity analyses were performed on all key model parameters. RESULTS: Use of IFNB-1b was associated with slower EDSS progression (longer time to MS diagnosis), and reduced relapse burden. In the base case (50-year time horizon), ICUR of IFNB-1b versus no treatment was a20,500 / QALY gained using Poser diagnostic criteria and dominates using McDonald diagnostic criteria. Findings were sensitive to simulation time horizon, IFNB-1b cost and treatment effect (underlying rate of disease progression). CONCLUSIONS: IFNB-1b-treatment of patients with a CIS appears to offer reasonable value for money relative to many well accepted health care interventions.
PND27 A DISCRETE EVENT SIMULATION OF PREGABALIN COMPARED TO USUAL CARE IN REFRACTORY NEUROPATHIC PAIN
Lister S 1 , Gordon JP 2 , McEwan P 2 1 Pfizer Limited, Tadworth, Surrey, UK, 2 CHKS Health Economics Unit, Cardiff, UK OBJECTIVES: Medicines must be shown to be both clinically and cost-effective compared to alternatives in order to be recommended by the National Health Service. This study evaluated the cost-effectiveness of pregabalin compared to usual care, in patients with refractory neuropathic pain (NeP), i.e., those who had achieved an inadequate response to, or were intolerant of, earlier medication including amitriptyline and gabapentin. METHODS: A Discrete Event Simulation (DES) model was constructed to evaluate clinical and economic outcomes of pregabalin versus usual care in patients with refractory NeP. An open-label, long term study evaluating pregabalin's effectiveness in refractory NeP patients over 15 months was used as the clinical input to the model. The 'usual care' comparator was defined as a group of pain medications comprising weak opioids, strong opioids, NSAIDs and/or analgesics. New utility data was collected using the EQ-5D via a UK postal survey of hospital patients with refractory NeP. This survey also collected costs of other pain medication and other health care resources consumed by patients. In each weekly cycle, patients accrued costs and benefits associated with their pain score in that cycle, which was uniquely defined by the input clinical data. Adverse events and withdrawals, and their cost and disutility, were estimated, also based on the input clinical data. Total costs and benefits were summed and extrapolated over the five-year time horizon of the model to calculate the ICER. RESULTS: The base case analysis estimated the ICER at £10,803/QALY. One-way sensitivity analyses showed that the ICER was stable to changes in all input parameters. CONCLUSIONS: This economic evaluation used new, real-world utility data in refractory NeP to show that pregabalin provides additional benefit in patients with refractory NeP at a reasonable cost. To our knowledge, this is the first economic model to specifically evaluate a refractory NeP population.
PND28 ADHERENCE AS A PREDICTOR OF THE UTILIZATION OF HEALTH CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING INTERFERONS
Faris R 1 , Steinberg S 1 , Chang CF 2 , Tang J 1 , Tankersley MA 1 1 Accredo Health Group, Memphis, TN, USA, 2 University of Memphis, Memphis, TN, USA OBJECTIVES: To determine if adherence to interferons used to treat patients with Multiple Sclerosis (MS) impacts the utilization of health care resources. METHODS: A retrospective cohort study design was used. Pharmacy and medical claims data for MS patients were extracted for 2006-2008. Adherence was measured using two methods for Medication Possession Ratio (MPR), one that incorporates persistence and one that does not. Patients were classified as adherent if they met a standard cutoff point. The number of hospitalizations, ER visits, and physician office visits were measured for each patient year. A series of regression models were used to assess the impact of adherence on the utilization of health care resources. RESULTS: A total of 3590 patients were included in the study. Based on the two MPR methods, compliance ranged from 77.6% to 89.8%. Patient adherence is a significant predictor of whether patients have at least 1 ER visit, with those who are adherent having a lower risk of ER visits. Patients considered adherent had a significantly lower risk of being admitted to the hospital than those considered non-adherent. Adherent patients were at higher risk of having at least 2 physician office visits. The full descriptive and inferential statistics, and individual year data will be included in the presentation. CONCLUSIONS: Interferon therapy is considered an effective treatment for MS patients. This study demonstrates that patient adherence to interferon therapy is important in reducing the use of expensive, acute health care resources. Patients who were adherent to the interferon therapy were less likely to have at least 1 ER visit and at least 1 hospitalization, and more likely to have at least 2 physician office visits. Reducing health care resource use can reduce the total cost of care for MS patients, and as well as increase an individual's long term productivity in society.
